nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyrimethamine—DHFR—Methotrexate—psoriasis	0.289	0.309	CbGbCtD
Pyrimethamine—CYP2C8—Tazarotene—psoriasis	0.154	0.165	CbGbCtD
Pyrimethamine—CYP2D6—Hydroxyurea—psoriasis	0.0692	0.0739	CbGbCtD
Pyrimethamine—CYP2C8—Cholecalciferol—psoriasis	0.0657	0.0702	CbGbCtD
Pyrimethamine—CYP2C8—Mycophenolate mofetil—psoriasis	0.057	0.0609	CbGbCtD
Pyrimethamine—CYP2C9—Cholecalciferol—psoriasis	0.0459	0.049	CbGbCtD
Pyrimethamine—CYP2C8—Hydrocortisone—psoriasis	0.0457	0.0489	CbGbCtD
Pyrimethamine—CYP2C8—Cyclosporine—psoriasis	0.0432	0.0462	CbGbCtD
Pyrimethamine—CYP2D6—Cholecalciferol—psoriasis	0.0419	0.0448	CbGbCtD
Pyrimethamine—CYP2C9—Cyclosporine—psoriasis	0.0301	0.0322	CbGbCtD
Pyrimethamine—CYP2C8—Dexamethasone—psoriasis	0.0284	0.0304	CbGbCtD
Pyrimethamine—CYP2D6—Cyclosporine—psoriasis	0.0276	0.0294	CbGbCtD
Pyrimethamine—CYP2C9—Dexamethasone—psoriasis	0.0198	0.0212	CbGbCtD
Pyrimethamine—CYP2D6—Dexamethasone—psoriasis	0.0181	0.0194	CbGbCtD
Pyrimethamine—Anaemia megaloblastic—Hydroxyurea—psoriasis	0.0058	0.14	CcSEcCtD
Pyrimethamine—Anaemia megaloblastic—Methotrexate—psoriasis	0.00217	0.0526	CcSEcCtD
Pyrimethamine—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00198	0.0875	CbGpPWpGaD
Pyrimethamine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00162	0.0718	CbGpPWpGaD
Pyrimethamine—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00161	0.0712	CbGpPWpGaD
Pyrimethamine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00151	0.067	CbGpPWpGaD
Pyrimethamine—Hypersensitivity—Calcipotriol—psoriasis	0.0013	0.0314	CcSEcCtD
Pyrimethamine—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.00122	0.0542	CbGpPWpGaD
Pyrimethamine—DHFR—G1/S-Specific Transcription—PCNA—psoriasis	0.00117	0.0517	CbGpPWpGaD
Pyrimethamine—Pancytopenia—Acitretin—psoriasis	0.00104	0.0251	CcSEcCtD
Pyrimethamine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.00101	0.0445	CbGpPWpGaD
Pyrimethamine—Anaphylactic shock—Beclomethasone—psoriasis	0.001	0.0242	CcSEcCtD
Pyrimethamine—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000997	0.0441	CbGpPWpGaD
Pyrimethamine—Erythema multiforme—Calcitriol—psoriasis	0.00093	0.0225	CcSEcCtD
Pyrimethamine—Haematuria—Acitretin—psoriasis	0.000929	0.0225	CcSEcCtD
Pyrimethamine—Pancytopenia—Hydroxyurea—psoriasis	0.000815	0.0197	CcSEcCtD
Pyrimethamine—Hypersensitivity—Clobetasol propionate—psoriasis	0.000811	0.0196	CcSEcCtD
Pyrimethamine—Hypersensitivity—Fluocinonide—psoriasis	0.000732	0.0177	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Calcitriol—psoriasis	0.000699	0.0169	CcSEcCtD
Pyrimethamine—DHFR—E2F mediated regulation of DNA replication—PCNA—psoriasis	0.000687	0.0304	CbGpPWpGaD
Pyrimethamine—Pancytopenia—Mycophenolic acid—psoriasis	0.000682	0.0165	CcSEcCtD
Pyrimethamine—Anorexia—Calcitriol—psoriasis	0.000666	0.0161	CcSEcCtD
Pyrimethamine—Haematuria—Mycophenolic acid—psoriasis	0.000611	0.0148	CcSEcCtD
Pyrimethamine—Decreased appetite—Calcitriol—psoriasis	0.000607	0.0147	CcSEcCtD
Pyrimethamine—Anorexia—Acitretin—psoriasis	0.000592	0.0143	CcSEcCtD
Pyrimethamine—Hypersensitivity—Methoxsalen—psoriasis	0.000577	0.014	CcSEcCtD
Pyrimethamine—Decreased appetite—Acitretin—psoriasis	0.00054	0.0131	CcSEcCtD
Pyrimethamine—Pancytopenia—Mycophenolate mofetil—psoriasis	0.000539	0.013	CcSEcCtD
Pyrimethamine—Leukopenia—Hydroxyurea—psoriasis	0.000535	0.0129	CcSEcCtD
Pyrimethamine—Hypersensitivity—Calcitriol—psoriasis	0.000515	0.0124	CcSEcCtD
Pyrimethamine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000509	0.0225	CbGpPWpGaD
Pyrimethamine—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000502	0.0222	CbGpPWpGaD
Pyrimethamine—Haematuria—Cyclosporine—psoriasis	0.000494	0.012	CcSEcCtD
Pyrimethamine—Haematuria—Mycophenolate mofetil—psoriasis	0.000482	0.0117	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Hydroxyurea—psoriasis	0.000478	0.0116	CcSEcCtD
Pyrimethamine—Anorexia—Hydroxyurea—psoriasis	0.000465	0.0112	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—CAT—psoriasis	0.000458	0.0203	CbGpPWpGaD
Pyrimethamine—Hypersensitivity—Acitretin—psoriasis	0.000458	0.0111	CcSEcCtD
Pyrimethamine—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.000457	0.011	CcSEcCtD
Pyrimethamine—Leukopenia—Mycophenolic acid—psoriasis	0.000448	0.0108	CcSEcCtD
Pyrimethamine—Vomiting—Calcitriol—psoriasis	0.000444	0.0107	CcSEcCtD
Pyrimethamine—Decreased appetite—Hydroxyurea—psoriasis	0.000424	0.0103	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—IL4—psoriasis	0.000421	0.0186	CbGpPWpGaD
Pyrimethamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000418	0.0185	CbGpPWpGaD
Pyrimethamine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000414	0.0183	CbGpPWpGaD
Pyrimethamine—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000412	0.0183	CbGpPWpGaD
Pyrimethamine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000412	0.0182	CbGpPWpGaD
Pyrimethamine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000409	0.0181	CbGpPWpGaD
Pyrimethamine—Thrombocytopenia—Mycophenolic acid—psoriasis	0.0004	0.00968	CcSEcCtD
Pyrimethamine—Vomiting—Acitretin—psoriasis	0.000395	0.00956	CcSEcCtD
Pyrimethamine—Vomiting—Fluocinolone Acetonide—psoriasis	0.000394	0.00953	CcSEcCtD
Pyrimethamine—Anorexia—Mycophenolic acid—psoriasis	0.000389	0.00942	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—CRP—psoriasis	0.000364	0.0161	CbGpPWpGaD
Pyrimethamine—Leukopenia—Cyclosporine—psoriasis	0.000363	0.00877	CcSEcCtD
Pyrimethamine—Hypersensitivity—Hydroxyurea—psoriasis	0.000359	0.00869	CcSEcCtD
Pyrimethamine—Decreased appetite—Mycophenolic acid—psoriasis	0.000355	0.00859	CcSEcCtD
Pyrimethamine—Leukopenia—Mycophenolate mofetil—psoriasis	0.000354	0.00856	CcSEcCtD
Pyrimethamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000339	0.015	CbGpPWpGaD
Pyrimethamine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000336	0.0149	CbGpPWpGaD
Pyrimethamine—Toxic epidermal necrolysis—Methotrexate—psoriasis	0.000335	0.0081	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—ICAM1—psoriasis	0.000334	0.0148	CbGpPWpGaD
Pyrimethamine—Anaphylactic shock—Cyclosporine—psoriasis	0.000331	0.008	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Cyclosporine—psoriasis	0.000324	0.00783	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000322	0.0078	CcSEcCtD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000316	0.014	CbGpPWpGaD
Pyrimethamine—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000316	0.00764	CcSEcCtD
Pyrimethamine—Anorexia—Cyclosporine—psoriasis	0.000315	0.00762	CcSEcCtD
Pyrimethamine—Vomiting—Hydroxyurea—psoriasis	0.00031	0.0075	CcSEcCtD
Pyrimethamine—Anorexia—Mycophenolate mofetil—psoriasis	0.000307	0.00744	CcSEcCtD
Pyrimethamine—Pancytopenia—Methotrexate—psoriasis	0.000305	0.00738	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Prednisolone—psoriasis	0.000301	0.00728	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Hydrocortisone—psoriasis	0.000294	0.00711	CcSEcCtD
Pyrimethamine—Decreased appetite—Cyclosporine—psoriasis	0.000287	0.00695	CcSEcCtD
Pyrimethamine—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000284	0.00687	CcSEcCtD
Pyrimethamine—Decreased appetite—Mycophenolate mofetil—psoriasis	0.00028	0.00678	CcSEcCtD
Pyrimethamine—Anorexia—Hydrocortisone—psoriasis	0.00028	0.00677	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Triamcinolone—psoriasis	0.000277	0.00669	CcSEcCtD
Pyrimethamine—Haematuria—Methotrexate—psoriasis	0.000273	0.00661	CcSEcCtD
Pyrimethamine—DHFR—G1/S Transition—PCNA—psoriasis	0.000264	0.0117	CbGpPWpGaD
Pyrimethamine—Vomiting—Mycophenolic acid—psoriasis	0.00026	0.00628	CcSEcCtD
Pyrimethamine—Decreased appetite—Hydrocortisone—psoriasis	0.000255	0.00618	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—IFNG—psoriasis	0.000254	0.0113	CbGpPWpGaD
Pyrimethamine—DHFR—Fluoropyrimidine Activity—TP53—psoriasis	0.000253	0.0112	CbGpPWpGaD
Pyrimethamine—Anaphylactic shock—Dexamethasone—psoriasis	0.000251	0.00607	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Betamethasone—psoriasis	0.000251	0.00607	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Betamethasone—psoriasis	0.000246	0.00594	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Dexamethasone—psoriasis	0.000246	0.00594	CcSEcCtD
Pyrimethamine—Hypersensitivity—Cyclosporine—psoriasis	0.000244	0.00589	CcSEcCtD
Pyrimethamine—Erythema multiforme—Methotrexate—psoriasis	0.000243	0.00588	CcSEcCtD
Pyrimethamine—Anorexia—Dexamethasone—psoriasis	0.000239	0.00579	CcSEcCtD
Pyrimethamine—Anorexia—Betamethasone—psoriasis	0.000239	0.00579	CcSEcCtD
Pyrimethamine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000238	0.00575	CcSEcCtD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—PCNA—psoriasis	0.000223	0.00986	CbGpPWpGaD
Pyrimethamine—Hypersensitivity—Prednisolone—psoriasis	0.000222	0.00536	CcSEcCtD
Pyrimethamine—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000219	0.0097	CbGpPWpGaD
Pyrimethamine—Anaphylactic shock—Prednisone—psoriasis	0.000219	0.00529	CcSEcCtD
Pyrimethamine—Decreased appetite—Dexamethasone—psoriasis	0.000218	0.00528	CcSEcCtD
Pyrimethamine—Decreased appetite—Betamethasone—psoriasis	0.000218	0.00528	CcSEcCtD
Pyrimethamine—Hypersensitivity—Hydrocortisone—psoriasis	0.000216	0.00524	CcSEcCtD
Pyrimethamine—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000216	0.00956	CbGpPWpGaD
Pyrimethamine—DHFR—Folate Metabolism—NFKB1—psoriasis	0.000212	0.00937	CbGpPWpGaD
Pyrimethamine—Vomiting—Cyclosporine—psoriasis	0.00021	0.00508	CcSEcCtD
Pyrimethamine—Anorexia—Prednisone—psoriasis	0.000208	0.00504	CcSEcCtD
Pyrimethamine—Vomiting—Mycophenolate mofetil—psoriasis	0.000205	0.00496	CcSEcCtD
Pyrimethamine—Hypersensitivity—Triamcinolone—psoriasis	0.000204	0.00493	CcSEcCtD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—PTTG1—psoriasis	0.0002	0.00887	CbGpPWpGaD
Pyrimethamine—Leukopenia—Methotrexate—psoriasis	0.0002	0.00485	CcSEcCtD
Pyrimethamine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00019	0.00842	CbGpPWpGaD
Pyrimethamine—Decreased appetite—Prednisone—psoriasis	0.00019	0.0046	CcSEcCtD
Pyrimethamine—Vomiting—Hydrocortisone—psoriasis	0.000187	0.00452	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Methotrexate—psoriasis	0.000183	0.00442	CcSEcCtD
Pyrimethamine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.00018	0.00796	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—PTTG1—psoriasis	0.000179	0.00793	CbGpPWpGaD
Pyrimethamine—Thrombocytopenia—Methotrexate—psoriasis	0.000179	0.00433	CcSEcCtD
Pyrimethamine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000178	0.00789	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000177	0.00785	CbGpPWpGaD
Pyrimethamine—Vomiting—Triamcinolone—psoriasis	0.000176	0.00425	CcSEcCtD
Pyrimethamine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000176	0.00778	CbGpPWpGaD
Pyrimethamine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000174	0.00772	CbGpPWpGaD
Pyrimethamine—Anorexia—Methotrexate—psoriasis	0.000174	0.00421	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—TNF—psoriasis	0.000165	0.00729	CbGpPWpGaD
Pyrimethamine—Hypersensitivity—Prednisone—psoriasis	0.000161	0.0039	CcSEcCtD
Pyrimethamine—Vomiting—Betamethasone—psoriasis	0.00016	0.00386	CcSEcCtD
Pyrimethamine—Vomiting—Dexamethasone—psoriasis	0.00016	0.00386	CcSEcCtD
Pyrimethamine—Decreased appetite—Methotrexate—psoriasis	0.000159	0.00384	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—TP53—psoriasis	0.000145	0.00643	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—NDUFA5—psoriasis	0.000143	0.00631	CbGpPWpGaD
Pyrimethamine—Vomiting—Prednisone—psoriasis	0.000139	0.00336	CcSEcCtD
Pyrimethamine—Hypersensitivity—Methotrexate—psoriasis	0.000135	0.00326	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—IL6—psoriasis	0.000133	0.00588	CbGpPWpGaD
Pyrimethamine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000133	0.00587	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—CYP2S1—psoriasis	0.000121	0.00537	CbGpPWpGaD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—TP53—psoriasis	0.000116	0.00515	CbGpPWpGaD
Pyrimethamine—Vomiting—Methotrexate—psoriasis	0.000116	0.00281	CcSEcCtD
Pyrimethamine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000104	0.00459	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—PCNA—psoriasis	8.17e-05	0.00362	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—PCNA—psoriasis	7.3e-05	0.00323	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—CARM1—psoriasis	5.92e-05	0.00262	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—NDUFA5—psoriasis	4.41e-05	0.00195	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.11e-05	0.00182	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—CYP2S1—psoriasis	3.75e-05	0.00166	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—CAT—psoriasis	3.64e-05	0.00161	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—HLA-A—psoriasis	3.62e-05	0.0016	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—NDUFA5—psoriasis	3.62e-05	0.0016	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—NDUFA5—psoriasis	3.59e-05	0.00159	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—APOE—psoriasis	3.38e-05	0.0015	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.34e-05	0.00148	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—NOS2—psoriasis	3.15e-05	0.00139	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—CYP2S1—psoriasis	3.08e-05	0.00136	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—CYP2S1—psoriasis	3.05e-05	0.00135	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—APOE—psoriasis	2.83e-05	0.00125	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—TP53—psoriasis	2.69e-05	0.00119	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—TYK2—psoriasis	2.58e-05	0.00114	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—PPARG—psoriasis	2.46e-05	0.00109	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—CD4—psoriasis	2.33e-05	0.00103	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.96e-05	0.000869	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—CARM1—psoriasis	1.83e-05	0.00081	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—STAT3—psoriasis	1.81e-05	0.000799	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.71e-05	0.000757	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.6e-05	0.000707	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—CARM1—psoriasis	1.5e-05	0.000665	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—CARM1—psoriasis	1.49e-05	0.000659	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.39e-05	0.000616	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—IL6—psoriasis	1.26e-05	0.000558	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—CAT—psoriasis	1.13e-05	0.000498	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—CAT—psoriasis	9.24e-06	0.000409	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—CAT—psoriasis	9.16e-06	0.000405	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—APOE—psoriasis	8.74e-06	0.000387	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—PPARG—psoriasis	7.61e-06	0.000337	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—APOE—psoriasis	7.18e-06	0.000318	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—APOE—psoriasis	7.11e-06	0.000315	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—PPARG—psoriasis	6.25e-06	0.000277	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—PPARG—psoriasis	6.2e-06	0.000274	CbGpPWpGaD
